Remdesivir is a delayed translocation inhibitor of SARS CoV-2 replication in vitro
Abstract
Remdesivir is a nucleoside analog approved by the FDA for treatment of COVID-19. Here, we present a 3.9-[A]-resolution cryoEM reconstruction of a remdesivir-stalled RNA-dependent RNA polymerase complex, revealing full incorporation of three copies of remdesivir monophosphate (RMP) and a partially incorporated fourth RMP in the active site. The structure reveals that RMP blocks RNA translocation after incorporation of three bases following RMP, resulting in delayed chain termination, which can guide the rational design of improved antiviral drugs.
02 /Specification & Classification
Click any tag to browse matching papers- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mechanism of SARS-CoV-2 polymerase inhibition by remdesivir
G. Kokic, H. S. Hillen, … P. Cramer·bioRxiv·Oct 28, 2020
- Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir
Wanchao Yin, Chunyou Mao, … H. Eric Xu·SciencePeer-reviewed·May 1, 2020
- Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target
- Structural basis for repurpose and design of nucleoside drugs for treating COVID-19
- Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir
M. Götte, C. J. Gordon, … D. P. Porter·bioRxiv·Oct 14, 2021
- Structural basis for selective remdesivir incorporation by SARS-CoV-2 RNA polymerase, and S759A resistance
Calvin J. Gordon, M.F. Oliva, … Kalyan Das·bioRxiv·Sep 4, 2025